|
KMID : 0939920170490041153
|
|
대한암학회지
2017 Volume.49 No. 4 p.1153 ~ p.1163
|
|
|
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor?Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
|
|
Suh Koung-Jin
Kim Se-Hyun
Lee Kyung-Hun
Kim Tae-Yong
Kim Yu-Jung
Han Sae-Won
Kang Eun-Young
Kim Eun-Kyu
Kim Ki-Dong
No Jae-Hong
Han Won-Shik
Noh Dong-Young
Lee Maria
Kim Hee-Seung
Im Seock-Ah
Kim Jee-Hyun
|
|
|
Abstract
|
|
|
Purpose: Although combining aromatase inhibitors (AI) with gonadotropin-releasing hormone agonists (GnRHa) is becoming more common, it is still not clear if GnRHa is as effective as bilateral salpingo-oophorectomy (BSO).
Materials and Methods: We retrospectively analyzed data of 66 premenopausal patients with hormone receptor? positive, human epidermal growth factor receptor 2?negative recurrent and metastatic breast cancer who had been treated with AIs in combination with GnRHa or BSO between 2002 and 2015.
Results: The median patient age was 44 years. Overall, 24 (36%) received BSO and 42 (64%) received GnRHa. The clinical benefit rate was higher in the BSO group than in the GnRHa group (88% vs. 69%, p=0.092). Median progression-free survival (PFS) was longer in the BSO group, although statistical significance was not reached (17.2 months vs. 13.3 months, p=0.245). When propensity score matching was performed, the median PFS was 17.2 months for the BSO group and 8.2 months for the GnRHa group (p=0.137). Multivariate analyses revealed that the luminal B subtype (hazard ratio, 1.67; 95% confidence interval [CI], 1.08 to 2.60; p=0.022) and later-line treatment (≥ third line vs. first line; hazard ratio, 3.24; 95% CI, 1.59 to 6.59; p=0.001) were independent predictive factors for a shorter PFS. Incomplete ovarian suppression was observed in a subset of GnRHa-treated patients whose disease showed progression, with E2 levels higher than 21 pg/mL.
Conclusion: Both BSO and GnRHa were found to be effective in our AI-treated premenopausal metastatic breast cancer patient cohort. However, further studies in larger populations are needed to determine if BSO is superior to GnRHa.
|
|
|
KEYWORD
|
|
|
Breast neoplasms, Premenopause, Aromatase inhibitors, Ovariectomy, Gonadotropin-releasing hormone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|